Screening Practices

TOTAL

n = 48

Academic

41 (85.4)

Community

7* (14.6)

p

Who should be screened?

0.558

   Almost no patients

3 (6.3)

3 (7.3)

0 (0.0)

   Symptomatic, high-risk

8 (16.7)

7 (17.1)

1 (14.3)

   All symptomatic patients

2 (4.2)

2 (4.9)

0 (0.0)

   Asymptomatic, high-risk

30 (62.5)

26 (63.4)

4 (57.1)

   Nearly all patients

5 (10.4)

3 (7.3)

2 (28.6)

Discuss cancer risk with asymptomatic patients

0.297

   Never

6 (12.5)

5 (12.2)

1 (14.3)

   <50% of the time

21 (43.8)

20 (48.8)

1 (14.3)

   >50% of the time

23 (25.0)

9 (22.0)

3 (42.9)

   Usually

5 (10.4)

4 (9.8)

1 (14.3)

   Almost always

4 (8.3)

3 (7.3)

1 (14.3)

Recommend screening for MSM

1.000

   Less likely

3 (6.25)

3 (7.3)

0 (0.0)

   More likely

45 (93.8)

38 (92.6)

7 (100.0)

Discuss multiple screening tests^a

0.608

   Never

16 (34.8)

15 (37.5)

1 (16.7)

   Rarely

15 (32.6)

12 (30.0)

3 (50.0)

   Sometimes

9 (19.6)

8 (20.0)

1 (16.7)

   Usually

3 (6.5)

2 (5.0)

1 (16.7)

   Don’t Screen

3 (6.5)

3 (7.5)

0 (0.0)

Perform/supervise screening^a

0.689

   Never

8 (18.2)

8 (21.2)

0 (0.0)

   Rarely

9 (20.5)

8 (21.1)

1 (16.7)

   Sometimes

9 (20.5)

8 (21.1)

1 (16.7)

   Usually

18 (40.9)

14 (36.8)

4 (66.7)

When is HRA recommended?

0.160

   Almost never

7 (14.6)

5 (12.2)

2 (28.6)

   At least one positive test

30 (62.5)

27 (65.9)

3 (42.9)

   If multiple positive tests

4 (8.3)

2 (4.9)

2 (28.6)

   All high-risk patients

3 (6.3)

3 (7.3)

0 (0.0)

   All patients

4 (8.3)

4 (9.8)

0 (0.0)